Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.

European heart journal·2016

Same author

Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials.

European journal of heart failure·2016

Same author

Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure　- Subanalysis of the WARCEF Trial.

Circulation journal : official journal of the Japanese Circulation Society·2016

Same author

Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study).

BMC neurology·2016

Same author

Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure.

Croatian medical journal·2016

Same author

The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure.

International journal of cardiology·2015

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Losartan: the dose does it.

Wolfram Doehner¹, Stephan von Haehling, Stefan D Anker

¹Center for Stroke Research Berlin - CSB, Campus Virchow-Medical Center, Charité Medical School, 13353 Berlin, Germany. wolfram.doehner@charite.de

Expert Opinion on Pharmacotherapy

|May 26, 2010

Summary

Higher doses of losartan (150 mg) significantly benefit patients with chronic heart failure compared to standard doses (50 mg). This approach can prevent major cardiovascular events in heart failure management.

Area of Science:

Cardiology
Pharmacology

Background:

Chronic heart failure (CHF) management necessitates a multi-pathway therapeutic strategy.
Optimal drug titration is often overlooked, potentially limiting treatment efficacy.

Discussion:

The Heart failure Endpoint evaluation with Angiotensin II Antagonist Losartan (HEAAL) study investigated losartan efficacy.
Findings indicate superior outcomes with 150 mg losartan versus 50 mg daily.

Key Insights:

A higher dose of losartan (150 mg) demonstrated favorable effects in CHF patients compared to the standard 50 mg dose.
Treatment with 150 mg losartan is estimated to prevent one primary event for every 31 patients over 4 years.

Outlook:

The HEAAL study results support optimizing losartan dosage for enhanced CHF treatment.

Related Experiment Videos

Last Updated: Jun 12, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Further discussion is warranted regarding current CHF treatment guidelines and high-dose losartan therapy.